:

TESLA SELL RATINGS DECLINE AS AI BET SHIFTS SENTIMENT

AI DESK■ 1 MIN READ
THU, OCT 1, 2026

■ AI-SUMMARIZED FROM 1 SOURCE ▸ TIMELINE

Tesla shares have fallen in 2026, yet Wall Street analysts are increasingly hesitant to issue sell recommendations. The shift reflects growing interest in Elon Musk's artificial intelligence initiatives.

Analyst coverage of Tesla is moving away from bearish calls despite the stock's poor performance this year. Major investment firms have trimmed their sell-side recommendations as confidence in the company's AI roadmap grows. Musk has positioned Tesla's future around autonomous driving and machine learning capabilities. The focus on AI development appears to be swaying analyst sentiment, even as traditional automotive metrics remain under pressure. The disconnect between stock performance and recommendation trends suggests analysts believe near-term headwinds may give way to longer-term gains tied to AI commercialization. Whether Musk's AI ambitions materialize as capital-efficient businesses will be central to Tesla's valuation recovery. Some analysts maintain cautious stances on near-term earnings, but fewer are recommending outright exits. The dynamic underscores how technological potential can influence investment theses independent of current financial results.

■ SOURCES

► Bloomberg Tech

■ SUMMARY WRITTEN BY AI FROM THE LINKS ABOVE

■ MORE FROM THE BUSINESS DESK

Saudi Arabia's Public Investment Fund is launching a new electric vehicle brand that will directly compete with Lucid Motors, the U.S. carmaker it already owns.

JUST NOW— Industry Desk

Taiwan Semiconductor Manufacturing Co. is evaluating a new campus in Texas as part of its ongoing US chipmaking expansion. The potential investment would represent a significant addition to TSMC's multiyear commitment to domestic chip production.

JUST NOW— AI Desk

Pershing Square CEO Bill Ackman says capital markets are narrowly concentrated on large initial public offerings. Anthropic, the AI startup behind Claude, is expected to go public this year.

7H AGO— Industry Desk

MercadoLibre's expansion into prescription drug sales in Brazil hit a regulatory hurdle as the country's health authority announced it is reviewing the e-commerce company's plan for an online pharmacy marketplace.

7H AGO— Industry Desk

■ SUBSCRIBE TO THE DAILY BRIEF

ONE EMAIL, 5 STORIES, 06:00 UTC. UNSUBSCRIBE ANYTIME.